MedinCell S.A. MDCLF
34.39 USD 0.00 (+0.00%)
At closeFeb 5, 2026, 4:00 PM EST
6.98 Day range 6.98
6.98 52-week range 34.39
- YTD
- +392.69%
- 1 year
- +392.69%
- Market cap
- 1.24B
- EPS (ttm)
- -1.09
- YTD return
- +392.69%
- 1-year return
- +392.69%
- Volume
- 21.64K
- Avg volume
- 9
- Open
- 6.99
- Previous close
- 34.39
- Day's range
- 6.98 – 6.98
- 52-week range
- 6.98 – 34.39
No chart data for this range yet.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jun 16, 2026 | Mar 31, 2026 | -0.25917 | -0.49493 | -0.24 | -90.97% |
| Dec 9, 2025 | Sep 30, 2025 | -0.30509 | -0.56644 | -0.26 | -85.66% |
| Jun 17, 2025 | Mar 31, 2025 | -0.45438 | -0.13327 | +0.32 | +70.67% |
| Dec 3, 2024 | Sep 30, 2024 | — | -0.54902 | — | — |
| Jun 25, 2024 | Mar 31, 2024 | — | -0.62587 | — | — |
| Dec 21, 2023 | Sep 30, 2023 | — | -0.30882 | — | — |
News
Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan 
MedinCell S.A. (MDCLF) Discusses U.S. Approval of Weltruza and Its Impact on Schizophrenia Treatment and Financial Outlook Transcript 
Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine) 
Medincell's Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026 
Medincell to Participate in Upcoming Investor Conferences 
Medincell: Publication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting 
Medincell Appoints Edna Venneker, MD, as Chief Medical Officer 
Medincell's Dr Grace Kim to Participate in Piper Sandler CNS Symposium 
Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook 
Medincell Continues to Strengthen and Renew its Board of Directors with the Proposed Appointment of Dr. Elisabeth Svanberg
Your note
Sign in to keep a note on MDCLF — it syncs with the Stock Master app.